COVID-19 RESOURCE CENTER

• CDC-Employees: How to Cope with Job Stress and Build Resilience During the COVID-19 Pandemic
• CDC-Healthcare Personnel and First Responders: How to Cope with Stress and Build Resilience During the COVID-19 Pandemic
• OSHA Guidance on Preparing Workplaces for COVID-19 (3/23/20)
• COVID-19 Treatment: A Review of Early and Emerging Options  (3/23/20)
• COVID-19 Resources for Pharmacists 
• State Data and Policy Actions to Address Coronavirus 
• WHO Coronavirus Disease (COVID-19) Outbreak 
• CDC Coronavirus (COVID-19) 
• FDA Coronavirus Disease 2019 (COVID-19) 
• CMS
• ONS Interim Guidelines During the COVID-19 Pandemic

• Providers Must Act by June 3, 2020 to Receive Additional Provider Relief Funds
• Provider Relief FAQs
• Husch Blackwell Resource for CARES Act frequently asked questions
• NHIA Cares Act Provider Relief Fund FAQ
• COVID-19 Legislative Response: Impact for Small Business
• Husch Blackwell (NHIA member) COVID-19 Resource Center
• Frier Levitt (NHIA member) COVID-19 Resource Center

• USP Response to Shortages of Garb and Personal Protective Equipment (PPE) for Sterile Compounding During COVID-19 Pandemic
• Compounding Alcohol-Based Hand Sanitizer During COVID-19 Pandemic
• Operational Considerations for Sterile Compounding During COVID-19 Pandemic

• Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency – Drug Information Update
• Compounding Alcohol-Based Hand Sanitizer During COVID-19 Pandemic(3/25/2020)
• CDC Strategies to Optimize the Supply of PPE and Equipment

• CDC Strategies for Optimizing the Supply of Facemasks
• CDC Recommended Guidance for Extended Use and Limited Reuse on N95 Filtering Facepiece Respirators in Healthcare Settings
• National Association for Home Care and Hospice
• American Association of Nurses
• CDC Coronavirus Disease 2019 (COVID-19) Caring for Someone at Home

NHIA

• HHS Letter
• Commercial Payer Recommendations

CMS

• CMS: Medicare FFS Response – MLN SE20011
• CMS: Guidance to Part C and Part D plans
• CMS Letter to Part D Plans – POD Signature
• CMS: Telehealth and Non-essential
• CMS State Coronavirus Waivers
• CMS Enrollment FAQ: CMS released frequently asked questions (FAQs) on provider enrollment, including waiver of certain screening requirements.
• Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to COVID-19 Public Health Emergency

DME MAC and other Medicare Contractors

• Use of CR Modifier and “COVID-19” Narrative on Specified Claims Due to the COVID-19 PHE
• Allowance for Dispensing in Excess of 30-day Supply of Enteral Nutrition During PHE
• DME MAC: Billing of Part B Drugs to DME MACs During COVID-19 Pandemic – Dispensing Amounts
• DME MAC POD Signature Guidance
• CGS Business Continuity: A Message from CGS DME Jurisdiction C Regarding COVID-19
• Noridian Business Continuity: A Message from Noridian Business Continuity
• OMHA Appeals
  Although Office of Medicare Hearings and Appeals (OMHA) office space is closed to the general public, OMHA remains open for business with employees working under maximum telework flexibilities per U.S. Office of Personnel Management guidance. OMHA hearings and appeals processing measures are proceeding as scheduled. Unless an appellant is notified directly that a hearing has been postponed or canceled, appellants should continue to appear for hearings by telephone as scheduled. The Chief Administrative Law Judge supports the Administrative Law Judges exercising flexibility with regard to reasonable requests to reschedule hearings. OMHA staff are responding to phone calls to adjudication team phones and toll-free lines. In an effort to continue operations as seamlessly as possible, minimal staff will be on-site in OMHA offices to receive and send mail and faxes. Additional information and updates will be provided as the situation evolves.
• Performant RAC Audits
  Performant RAC Region 5 is following CMS’ guidance during this Covid-19 emergency. As of March 18, 2020 we will not be sending any new Additional Documentation Request (ADR) letters for 30 days. We are flexible with providers and suppliers with returning medical documentation. If a supplier is having difficulties gathering/submitting documentation, please have them contact our customer service number or email and let us know. We will grant an extension. Automated reviews are not impacted, however a provider/supplier can request a discussion period and if they have difficulties gathering/submitting medical records, please have them contact our customer service number or email and let us know. We will grant an extension. Our customer service number is 866-201-0580 and our email address is: info@performantrac.com
• CMS- Pending: Sequestration
  The COVID 3 bill suspends Medicare Sequestration May 1, 2020 December 31, 2020

Other

• Express Script COVID-19 Signature Log
• Durable Medical Equipment, Prosthetics, Orthotics and Supplies: CMS Flexibilities to Fight COVID-19
• Aetna: Waive Copay for COVID related Hospitalization
• Kaiser: COVID State info

• RAP COVID-19 Vaccine Tracker
• Gilead Remdesivir Pharmacy Guide – May 2020
• Remdesivir IV EUA Guidelines
• Remdesivir Injection 100 mg Pharmacy Manual
• BIO COVID-19 Therapuetic Development Tracker
• CMS Publishes Information for Pharmacies and Other Suppliers on Temporarily Enrolling as Independent Clinical Diagnostic Laboratories
• The Compliance Team Webinar: COVID-19: The Critical Role of Laboratory Testing
• Compassionate Use of Remdesivir for Patients with Severe COVID-19 (4/10/2020)
• Are Patient with hypertensions and diabetes mellitus at increased risk for COVID-19 infection?
• NEJM
• FDA Drug Shortages 
•  The Joint Commission
• CHAP
• Infectious Diseases Society of America
• ASHP Coronavirus Disease 2019 Resource Center
• Elsevier Resource Novel Coronavirus Information Center
• Premier Safety Institute
• Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
• MMWR Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19
• Studies Estimate Incubation Time, Infectious Period of SARS-CoV-2
• Positive RT-PCR test Results in Patient Recovered from COVID-19
• Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics
• Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents
• Transmission of 2019-nCOV Infection from an Asymptomatic Contact in Germany
• NIH clinical trial of remdesivir to treat COVID-19 begins
• Remdesivir for Potential Treatment of COVID-19
• Presumed Asymptomatic Carrier Transmission of COVID-19
• Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

• Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations
• Three Coronavirus Vaccine Developers Report Promising Initial Results
• An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

• Policy on Certain Hospital Drugs compounded by pharmacies not registered as outsourcing
• Non-Standard PPE Policy for Compounders not registered as outsourcing
• Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency
• Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency